By SPC News Staff
The FDA approved edaravone (Radicava ORS, Mitsubishi Tanabe Pharma Corporation) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease.
Radicava ORS is an orally administered formulation of Radicava, which was originally approved in 2017, as an IV infusion to treat ALS.
Edaravone oral suspension is self-administered and can be taken at home. After fasting overnight, edaravone ORS should be taken in